IMUX logo

IMMUNIC INC

IMUXNASDAQ
πŸ† #3974 by market capUS Equity
$857.50β–Ό $63.71 (βˆ’7.43%)
Simulated price
πŸ””
Track IMUX
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 7.4%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$130M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
β€”
Otter Score
48
Weak
No chart data available for IMUX.

Trading Snapshot

Day Range
$846.91 – $874.51
52-Week Range
$5.06 – $17.43
Volume
$3.25B
Avg Volume
$2.71B
Shares Outstanding
13.6M
Next Earnings
Nov 24, 2026

Fundamentals Snapshot

Annual Revenue
$9M
Last Q Revenue
$2M
P/E Ratio
β€”
P/S Ratio
β€”
EPS (TTM)
$-4.20
Dividend Yield
β€”
Dilution (1yr)
+33.5%

Why Investors Own IMUX

  • βœ“High-growth profile β€” revenue up +52.8% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 32% gross margin and 8% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

IMUX logo

IMMUNIC INC

IMUX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0β–² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$103Mβ–² +5.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$86Mβ–² +1.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
12.0Mβ–² +33.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$15Mβ–Ό βˆ’$20M YoY
StockOtter Β· stockotter.space

About IMMUNIC INC

Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORΞ³t, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
48/100

Analyst Price Target

β“˜
Average Target
$854.64
β–Ό βˆ’0.3% Downside
High Target$945.63
Low Target$790.07
Based on 34 analysts

Latest News & Updates

πŸš€
BloombergΒ·2h ago

IMMUNIC INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

πŸ›°οΈ
Barron’sΒ·5h ago

Analysts lift IMUX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatchΒ·1d ago

IMMUNIC INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.